- 询价
- Nebulabio
- 中国
- NBAB-193203
- 2026年01月05日
- WB
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human Trefoil Factor 3 protein
- 形态：
liquid
- 克隆性：
单克隆
- 保质期：
见COA
- 库存：
大量
- 供应商：
北京辰辉创聚生物技术有限公司
- 应用范围：
WB
- 靶点：
Trefoil Factor 3
- 抗体英文名：
Anti-Trefoil Factor 3 Monoclonal Antibody
- 抗体名：
抗Trefoil Factor 3单抗
- 规格：
100ul; 500ul; 1ml
| 产品信息
品名：NebuSelect™ Anti-Trefoil Factor 3 Monoclonal Antibody
别名：hITF, hP1.B, Intestinal trefoil factor, ITF, mITF, P1B, Polypeptide P1.B, TFF3, TFI, TREFOIL, Trefoil factor 3
货号：NBAB-193203
品牌：Nebulabio
规格：100ul; 500ul; 1ml
| 产品描述
NebuSelect™ Anti-Trefoil Factor 3 Monoclonal Antibody (Cat# NBAB-193203) was produced in rabbits immunized with recombinant Human Trefoil Factor 3 protein, and it reacts with Human. This antibody is validated for WB.
| 产品属性
Product Category：Rabbit MAb
Reactivity：Human
Specificity：Human Trefoil Factor 3
Immunogen：Recombinant Human Trefoil Factor 3 protein
Isotype：Monoclonal Rabbit IgG
Purification：Protein A & Protein G Affinity Purification
Buffer：0.2 μm filtered solution in PBS, pH7.4, containing 0.09% Sodium azide, 50% glycerol.
Conjugate：Unconjugated
Applications：WB
Dilution：WB: 1:1000～1:5000
Storage：This liquid antibody can be stored at 2℃-8℃ for at least two weeks. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20℃. When reconstituted in sterile pH 7.4 0.01M PBS or antibody diluent, the antibody is stable for at least two weeks at 2-4℃.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Purification, Quantification, and Functional Analysis of Complement Factor H
a monoclonal anti-FH antibody as ligand. Other affinity chromatography ligands, including cardiolipin and trinitrophenyl-bovine serum albumin (TNP-BSA), can be used to purify human FH and also FH from a wide range of vertebrates, including mammals, birds, bony
医学生理病理与临床分册2000，20（2）：137-140.[5]Yang XD，Jia XC，Corvalan JR， etal.Development of ABX-EGF，a fully human anti-EGF receptor monoclonal antibody，forcancertherapy.Hematology， 2001，38：17-13．[6]Herbst RS，langer CJ.Epidermal growth factor receptors as a target
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
技术资料暂无技术资料 索取技术资料
